Lin Yan, Jung Hyeim, Bulman Christina A, Ng James, Vinck Robin, O'Beirne Cillian, Zhong Shuai, Moser Matthew S, Tricoche Nancy, Peguero Ricardo, Li Robert W, Urban Joseph F, Le Pape Patrice, Pagniez Fabrice, Moretto Marco, Weil Tobias, Lustigman Sara, Cariou Kevin, Mitreva Makedonka, Sakanari Judy A, Gasser Gilles
Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, 75005 Paris, France.
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
J Med Chem. 2023 Dec 14;66(23):15867-15882. doi: 10.1021/acs.jmedchem.3c01333. Epub 2023 Nov 27.
Drug resistance observed with many anti-infectives clearly highlights the need for new broad-spectrum agents to treat especially neglected tropical diseases (NTDs) caused by eukaryotic parasitic pathogens, including fungal infections. Herein, we show that the simple modification of one of the most well-known antifungal drugs, fluconazole, with organometallic moieties not only improves the activity of the parent drug but also broadens the scope of application of the new derivatives. These compounds were highly effective in vivo against pathogenic fungal infections and potent against parasitic worms such as , which causes lymphatic filariasis and , one of the soil-transmitted helminths that infects millions of people globally. Notably, the identified molecular targets indicate a mechanism of action that differs greatly from that of the parental antifungal drug, including targets involved in biosynthetic pathways that are absent in humans, offering great potential to expand our armamentarium against drug-resistant fungal infections and neglected tropical diseases (NTDs) targeted for elimination by 2030.
许多抗感染药物出现的耐药性问题,凸显了研发新型广谱药物的必要性,特别是用于治疗由真核寄生虫病原体引起的被忽视的热带病(NTDs),包括真菌感染。在此,我们表明,对最著名的抗真菌药物之一氟康唑进行简单的有机金属部分修饰,不仅提高了母体药物的活性,还拓宽了新衍生物的应用范围。这些化合物在体内对致病性真菌感染具有高效,对诸如引起淋巴丝虫病的寄生虫以及全球感染数百万人的土源性蠕虫之一有效。值得注意的是,所确定的分子靶点表明其作用机制与母体抗真菌药物有很大不同,包括涉及人类不存在的生物合成途径的靶点,这为扩大我们对抗耐药真菌感染和到2030年要消除的被忽视热带病(NTDs)的武器库提供了巨大潜力。